710 A.H. Lichtman and B.R. Martin
approach examining molecular and cellular changes in conjunction with animal
models of dependence, and clinical trials will undoubtedly further our basic un-
derstanding of cannabinoid dependence as well as develop pharmacotherapies for
cannabinoid dependence disorders.
Acknowledgements.
This work was supported by NIH grants DA03672, DA005274, DA14277, and DA15197.
References
Aceto M, Scates S, Lowe J, Martin B (1995) Cannabinoid precipitated withdrawal by the
selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 282:R1–R2
Aceto M, Scates S, Lowe J, Martin B (1996) Dependence on∆9-tetrahydrocannabinol: studies
on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290–1295
Aceto MD, Scates SM, Razdan RK, Martin BR (1998) Anandamide, an endogenous cannabi-
noid, has a very low physical dependence potential. J Pharmacol Exp Ther 287:598–605
Aceto MD, Scates SM, Martin BB (2001) Spontaneous and precipitated withdrawal with
a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 416:75–81
Anthony J, Warner L, Kessler R (1994) Comparative epidemiology of dependence on to-
bacco, alcohol, controlled substances and inhalants: basic findings from the National
Comorbidity Survey. Exp Clin Psychopharmacol 2:244–268
Bass C, Welch S, Martin B (2004) Reversal of delta(9)-tetrahydrocannabinol-induced toler-
ance by specific kinase inhibitors. Eur J Pharmacol 496:99–108
Bass CE, Martin BR (2000) Time course for the induction and maintenance of tolerance to
delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 60:113–119
Beardsley PM, Martin BR (2000) Effects of the cannabinoid CB(1) receptor antagonist,
SR141716A, after delta(9)-tetrahydrocannabinol withdrawal. Eur J Pharmacol 387:47–
53
Beardsley PM, Balster RL, Harris LS (1986) Dependence on tetrahydrocannabinol in rhesus
monkeys. J Pharmacol Exp Ther 239:311–319
Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, Le
Fur G, Casellas P (1995) Activation of mitogen-activated protein kinases by stimulation
of the central cannabinoid receptor CB1. Biochem J 312:637–641
Braida D, Pozzi M, Cavallini R, Sala M (2001a) Conditioned place preference induced by
the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience
104:923–926
Braida D, Pozzi M, Parolaro D, Sala M (2001b) Intracerebral self-administration of the
cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system.
Eur J Pharmacol 413:227–234
BreivogelCS,ChildersSR,DeadwylerSA,HampsonRE,VogtLJ,Sim-SelleyLJ(1999)Chronic
delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid
receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem
73:2447–2459
Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawal among adults seeking treat-
ment for marijuana dependence. Addiction 94:1311–1322
Budney AJ, Hughes JR, Moore BA, Novy PL (2001) Marijuana abstinence effects in marijuana
smokers maintained in their home environment. Arch Gen Psychiatry 58:917–924
Budney AJ, Moore BA, Vandrey RG, Hughes JR (2003) The time course and significance of
cannabis withdrawal. J Abnorm Psychol 112:393–402